First of all, most specific inhibitors of HDAC are not permeable to the BBB; secondly, unspecific HDAC inhibitors were associated with several adverse effects such as weight loss, taste disturbances, electrolyte changes, and cardiac arrhythmias in stroke Phase I/II clinical studies [73]. This evidence concerns the gene HDAC9 and cardiac rhythm disease.